HGH Fragment 176-191 for Laboratory Research

HGH Fragment 176-191, or hGH(176–191), is the native C-terminal 16-residue segment of the mature 191-residue human hGH chain. Its sequence is FLRIVQCRSVEGSCGF, beginning with phenylalanine at position 176. Numbering refers to the mature chain recorded under UniProt P01241, not to the longer preprotein. P01241 identifies the parent protein rather than providing a separate accession for the isolated fragment.

PubChem depicts the reference peptide with a disulphide bond between Cys7 and Cys14 of the fragment, corresponding to Cys182 and Cys189 in mature-chain numbering. The two PubChem records below describe reference structures with that closed bond. They define database identities but do not determine the oxidation state, counter-ion or composition of supplied material.

Reference formulae, masses and identifiers cannot authenticate a commercial sample. Sequence, terminal chemistry, counter-ion, disulphide state, label and batch code must converge in matching analytical documentation before a supplied material can be assigned this identity.

Research source: Ng et al. 1978 · PMID 645904

Similar catalogue wording can conceal chemically different analytes. Unmodified hGH(176–191), AOD-9604, native hGH(177–191) and full-length mature hGH must therefore remain separate in literature review, procurement and batch documentation. Sequence ancestry is a structural relationship; it is not evidence that related molecules share properties.

The distinction controls how evidence is read. Three of the six listed sources concern the shorter native hGH(177–191) or peptides containing that sequence, while one review concerns AOD-9604. Those records cannot fill evidence gaps for unmodified hGH(176–191). A name on an experimental material also does not establish that its sequence, molecular form and analytical identity match a database record or supplied batch.

Delimitation sources: Weerasinghe et al. 1979 · PMID 373464 · Macaulay et al. 1983 · PMID 6307153 · Wilding 2004 · PMID 15134286

This section describes findings in controlled research. The records span preclinical rat models, isolated rat material, a review and a cell-culture formulation. Every observation remains attached to its named analyte, model, method and endpoint; the records do not form one pooled evidence set.

Only Ng 1978 explicitly examined native hGH(176–191), and it did so among several C-terminal fragments in a preclinical rat model. The remaining records concern a different analyte or a multi-component formulation. None authenticates a Reborn Peptides batch.

Evidence map: PMID 645904 · PMID 373464 · PMID 6307153 · PMID 8358331 · PMID 15134286 · PMID 35783198

HGH Fragment 176-191, hGH(176–191), somatotropin fragment 176–191 and HGH Frag 176 191 can denote the same native 16-residue identity when the sequence definition agrees. Abbreviated wording does not relax the requirement to verify the complete sequence, molecular form and batch traceability.

The neutral free-peptide record and the acetic-acid-containing reference record are not interchangeable. Their documented masses differ by 60.0 g/mol, corresponding to the acetic-acid component in CID 172966176. A different counter-ion, terminal chemistry or disulphide state requires its own verified formula and mass; neither reference record proves the composition of supplied material.

Three levels must remain distinct. Database identity describes a curated reference structure. Experimental material is the analyte reported by a publication and remains bounded by that paper's characterisation. Supplied material requires a matching label, specification, batch code and analytical documentation. Agreement at one level cannot be treated as evidence at another.

The six publications do not establish a uniform profile for hGH(176–191). They do not verify identity, content, purity, counter-ion, oxidation state, stability or suitability of a Reborn Peptides batch. Literature frames model-specific questions, whereas batch analysis documents the named sample tested.

Evidence-boundary sources: Ng et al. 1978 · PMID 645904 · Habibullah et al. 2022 · PMID 35783198

No physical form, stated content, counter-ion or storage temperature is asserted here. Each must be reconciled against the released label, product specification and documentation for the applicable batch. Catalogue wording or a database reference cannot establish these properties.

The required documentation chain should connect HGH Fragment 176-191, SKU FR5, label, batch code, specification, analytical method, test date and result. A COA should identify the analyte as hGH(176–191) and link every reported result to the tested batch. Any discrepancy should be resolved before the material is assigned to controlled laboratory research.

Any numerical purity statement must be batch-specific and method-specific. HPLC can describe the chromatographic result for the analysed sample, but does not by itself establish complete sequence, counter-ion, terminal chemistry or disulphide connectivity. Identity testing and chromatographic assessment answer complementary questions, and neither result may be transferred to another batch.

HGH Fragment 176-191 is presented to EU laboratories as research material. Published records describe named analytes and experimental systems; they neither certify supplied material nor replace a released specification and matching batch documentation.

Research use only. For laboratory research only. Not for human or veterinary use. Not intended to diagnose, treat, cure or prevent any disease. Not a medicinal product, food or cosmetic.